查詢結果分析
相關文獻
- Resistance-associated Substitution and Ledipasvir/sofosbuvir Therapy in Mongolian Chronic Hepatitis C Patients
- Resistance-associated Substitution and Ledipasvir/sofosbuvir Therapy in Mongolian Chronic Hepatitis C Patients
- 第一型慢性C型肝炎全口服治療新藥Ledipasvir/Sofosbuvir (Harvoni®)
- Sofosbuvir慢性C型肝炎全口服治療新藥
- Sofosbuvir併用Amiodarone可能導致嚴重心搏過緩
- Sofosbuvir/velpatasvir/voxilaprevir Plus Ribavirin for Chronic Hepatitis C Patients with Direct Acting Antiviral Failures: Implications for Viral Elimination in Taiwan
- 對文革時期內蒙科爾沁左翼後旗「民族分裂案」的實證考察
- Sofosbuvir/velpatasvir/voxilaprevir Plus Ribavirin for Chronic Hepatitis C Patients with Direct Acting Antiviral Failures: Implications for Viral Elimination in Taiwan
- Recent Improvement in Particulate Matter (PM) Pollution in Ulaanbaatar, Mongolia
- Recent Improvement in Particulate Matter (PM) Pollution in Ulaanbaatar, Mongolia
頁籤選單縮合
題名 | Resistance-associated Substitution and Ledipasvir/sofosbuvir Therapy in Mongolian Chronic Hepatitis C Patients= |
---|---|
作者 | Hsu, Shih-jer; Enkhzaya, Sukhee; Lin, You-yu; Tseng, Tai-chung; Khosbayar, Tulgaa; Tsai, Cheng-hsueh; Wang, Tzu-san; Enkhtuya, Damba; Ivshinkhorol, Dogsom; Naranzul, Nyamsuren; Jargalsaikhan, Badarch; Amarsanaa, Jazag; Baatarkhuu, Oidov; Kao, Jia-horng; |
期刊 | Journal of the Formosan Medical Association |
出版日期 | 20200300 |
卷期 | 119:3 2020.03[民109.03] |
頁次 | 頁712-719 |
分類號 | 418.285 |
語文 | eng |
關鍵詞 | Chronic hepatitis C; Resistance-associated substitution; Ledipasvir; Sofosbuvir; Mongolia; |